IMMUNOVANT, INC. Accounts Payable
IMMUNOVANT, INC. (IMVT) had Accounts Payable of $10.14 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $10.14M.
- 2026-03-31: Accounts Payable, Current $7.54M.
- 2025-12-31: Accounts Payable, Current $8.62M.
- 2025-09-30: Accounts Payable, Current $6.92M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $10.14M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.54M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $8.62M 10-Q · filed 2026-02-06 |
| 2025-09-30 | $6.92M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $7.84M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $17.66M 10-K · filed 2026-05-20 |
| 2024-12-31 | $19.82M 10-Q · filed 2025-02-06 |
| 2024-09-30 | $20.73M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $11.04M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $7.16M 10-K · filed 2025-05-29 |
| 2023-12-31 | $3.91M 10-Q · filed 2024-02-12 |
| 2023-09-30 | $7.51M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $26.46M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $1.35M 10-K · filed 2024-05-29 |
| 2022-12-31 | $14.00M 10-Q · filed 2023-02-03 |
| 2022-09-30 | $7.46M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $1.07M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $18.63M 10-K · filed 2023-05-22 |
| 2021-12-31 | $3.83M 10-Q · filed 2022-02-04 |
| 2021-09-30 | $4.24M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $3.11M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $2.43M 10-K · filed 2022-06-08 |
| 2020-12-31 | $2.10M 10-Q · filed 2021-02-16 |
| 2020-09-30 | $5.79M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $8.01M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $1.19M 10-K · filed 2021-06-01 |
| 2019-12-31 | $2.81M 10-Q · filed 2020-02-14 |
| 2019-03-31 | $206.00K 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |